Hepion Pharmaceuticals and Pharma Two B have terminated a reverse merger agreement that was expected to close by the end of the year. The decision was mutual, meaning neither company will have to ...

The focus of the combined company is developing new treatment for rare genetic skin diseases. Palvella Therapeutics completed a reverse merger with Pieris Pharmaceutical of Boston to become a ...

“This reverse merger represents a US$452 million transaction at a deemed price of US$3.20 per share —a significant milestone that we believe will enhance market visibility while supporting our ...